SecBot SecBot
8-K ·Filed Nov 5, 2026

TMDX

TransMedics Group, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed11d 11h ago SEC0001193125-26-449729
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q3 beat and raised guidance signal accelerating momentum in the core NOP business ahead of ENHANCE Heart Part B and DENOVO Lung catalysts. Monitor the Q4 call for initial enrollment updates on these trials and European NOP launch progress.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$88.24
T+0 close · Nov 5, 2026 · via day close
Latest settled
+3.56%
T+5 · $91.38 · next T+20 in 20d
Vs SPY
+0.96%
α at T+5
Latest observation
+4.82%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $88.24entry
  2. T+1 · 8d ago +6.29%α +3.92% · $93.79
  3. T+5 · 4d ago +3.56%α +0.96% · $91.38
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP EPS of $0.46, beating consensus estimates of $177.1M and $0.29. The company raised full-year 2026 revenue guidance to $764-$774M (including PAD Aviation), up from prior guidance of $737-$757M, driven by record case volume and strong execution in the National OCS Program.

Key Financial Metrics

EPS (Adj.)
$0.51
est $0.29 · +75.9% · GAAP: $0.46
Revenue
$203.0M
est $177.1M · +14.6% · +41.0% YoY
Rating
strong beat
Guidance
$764M-$774M
raised
Gross Margin
58.5%

Key Facts

  • Q3 2026 total revenue of $203.0M, up 41% YoY from $143.8M
  • GAAP diluted EPS of $0.46 vs consensus $0.29 (beat by 58.6%)
  • Adjusted diluted EPS of $0.51 vs consensus $0.29 (beat by 75.9%)
  • Full-year 2026 revenue guidance raised to $764-$774M from $737-$757M
  • Organic revenue growth (ex-PAD Aviation) was 34.6% in Q3
  • Service revenue grew 60% YoY to $89.6M; organic service revenue growth was 42.8%
  • Operating income of $28.1M, up 21% YoY; operating margin 13.9%
  • Cash balance of $493.0M as of September 30, 2026
  • Received FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials in October
  • Awarded first European transplant logistics tender in Italy

Financial Impact

Revenue beat consensus by $25.9M (14.6%); EPS beat by $0.17 (58.6%); guidance raised by $27M at midpoint

revenueepsguidanceoperating incomecash

Segment Breakdown

SegmentRevenueGrowth
Net product revenue$113.4M+29.0%
Service revenue$89.6M+60.0%

Risk Factors

  • GAAP net income declined YoY ($17.1M vs $24.3M) due to higher operating expenses and interest costs
  • Operating margin contracted 230bps YoY to 13.9% as investments in R&D and infrastructure outpace revenue growth
  • Diluted share count increased to 40.8M from 40.7M YoY, pressuring per-share metrics
  • PAD Aviation contributed $9.4M in Q3 revenue; integration and profitability trajectory remain unproven

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
74% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449729
Document: tmdx-20261105.htm0001193125-26-449729
Document: 0001193125-26-449729-index-headers.html0001193125-26-449729
Document: 0001193125-26-449729-index.html0001193125-26-449729
Document: 0001193125-26-449729.txt0001193125-26-449729
8-K Data (Synthetic)0001193125-26-449729

Track record

9 reports on TMDX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +22.27% at T+60 after the Jun 11, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $90.95 Now $92.21 +1.39% settles Nov 17
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $88.24 to $91.38 Now $92.21 +4.50% ▲ +3.56% +0.96% vs SPY
  3. Nov 5, 202611d ago Press Release Bullish 6/10 No price data
  4. Jun 12, 202622w ago Institutional Cluster Bullish 6/10 Entry $72.91 to $78.79 Now $92.21 +26.47% ▲ +8.06% +7.39% vs SPY
  5. Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $73.59 to $73.22 Now $92.21 +25.30% ▼ −0.50% −0.94% vs SPY
  6. Apr 10, 202631w ago DEFA14A Neutral 3/10 Entry $114.00 to $115.87 Now $92.21 −19.11% ▲ +1.64% −2.86% vs SPY
  7. Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $147.00 to $134.77 Now $92.21 −37.27% ▼ −8.32% −7.11% vs SPY
  8. Feb 27, 202637w ago 8-K Neutral 4/10 Entry $145.26 to $129.61 Now $92.21 −36.52% ▼ −10.77% −8.79% vs SPY
  9. Feb 24, 202637w ago 8-K Bullish 8/10 Entry $131.85 to $147.66 Now $92.21 −30.06% ▲ +11.99% +13.09% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026